In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex®, would ...

Look for IonQ to continue pursuing attractive opportunities in 2026. One deal is already on the horizon, assuming it doesn't ...

The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry ...

VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...

The head of Britain's Secret Intelligence Service, the foreign spy service known as MI6, will warn that Russia poses an ...

-- Globally recognized pediatric epileptologist and clinical researcher brings deep expertise in Dravet syndrome and genetic medicine -- ...

Rapid innovation, expanding clinical pipelines, and rising demand for curative treatments position gene therapy as a ...

The study points up interpretability as a critical barrier to trust and adoption. Many AI-based cybersecurity tools function ...

As cyber threats grow faster than organisations can adapt, 2026 is shaping up to be the year when digital resilience becomes the true measure of operational survival ...

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...